Join
Live feed
·
INSIDERFilingvia Quantisnow
Sonnet BioTherapeutics Holdings Inc. logo

Chief Technical Officer Dexter Susan was granted 8,000 shares, increasing direct ownership by 487% to 9,643 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SONN (Sonnet BioTherapeutics Holdings Inc.) and more on Quantisnow.